CALQUENCE®▼ (acalabrutinib)
CALQUENCE® (acalabrutinib) is een remmer van het Bruton Tyrosine Kinase (BTK)
voor de behandeling van chronische lymfatische leukemie (CLL).1
Referenties
1. CALQUENCE® SKP
3. Barf T, et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther. 2017;363(2):240-252.
4. Bond DA, et al. Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019;14(3):197-205.
5. Sharman JP, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up. Presentation presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021 (Virtual meeting).
6. Sharman JP et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022; doi: 10.1038/s41375-021-01485-x.
7. Data on File, REF-113076. AstraZeneca Pharmaceuticals LP.
8. Byrd JC, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021; published online on Jul 26: DOI https://doi.org/101200/JCO.21.01210.
9. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presentation presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-31, 2020 (Virtual Meeting).
10. Shanafelt et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017 Jul;58(7):1630-1639.
11. Ghia P, et al. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic LymphocyticLeukemia: Final ASCEND Trial Results. Hemasphere. 2022 Nov 14;6(12): 1-10.